» Articles » PMID: 25659907

Stabilizing a Flexible Interdomain Hinge Region Harboring the SMB Binding Site Drives UPAR into Its Closed Conformation

Overview
Journal J Mol Biol
Publisher Elsevier
Date 2015 Feb 10
PMID 25659907
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

The urokinase-type plasminogen activator receptor (uPAR) is a multidomain glycolipid-anchored membrane protein, which facilitates extracellular matrix remodeling by focalizing plasminogen activation to cell surfaces via its high-affinity interaction with uPA. The modular assembly of its three LU (Ly6/uPAR-like) domains is inherently flexible and binding of uPA drives uPAR into its closed conformation, which presents the higher-affinity state for vitronectin thus providing an allosteric regulatory mechanism. Using a new class of epitope-mapped anti-uPAR monoclonal antibodies (mAbs), we now demonstrate that the reciprocal stabilization is indeed also possible. By surface plasmon resonance studies, we show that these mAbs and vitronectin have overlapping binding sites on uPAR and that they share Arg91 as hotspot residue in their binding interfaces. The crystal structure solved for one of these uPAR·mAb complexes at 3.0Å clearly shows that this mAb preselects the closed uPAR conformation with an empty but correctly assembled large hydrophobic binding cavity for uPA. Accordingly, these mAbs inhibit the uPAR-dependent lamellipodia formation and migration on vitronectin-coated matrices irrespective of the conformational status of uPAR and its occupancy with uPA. This is the first study to the best of our knowledge, showing that the dynamic assembly of the three LU domains in uPARwt can be driven toward the closed form by an external ligand, which is not engaging the hydrophobic uPA binding cavity. As this binding interface is also exploited by the somatomedin B domain of vitronectin, therefore, this relationship should be taken into consideration when exploring uPAR-dependent cell adhesion and migration in vitronectin-rich environments.

Citing Articles

Targeted imaging of uPAR expression in vivo with cyclic AE105 variants.

Leth J, Newcombe E, Gronnemose A, Jorgensen J, Qvist K, Clausen A Sci Rep. 2023; 13(1):17248.

PMID: 37821532 PMC: 10567728. DOI: 10.1038/s41598-023-43934-w.


High-throughput optofluidic screening of single B cells identifies novel cross-reactive antibodies as inhibitors of uPAR with antibody-dependent effector functions.

Lourenco A, Chuo S, Bohn M, Hann B, Khan S, Yevalekar N MAbs. 2023; 15(1):2184197.

PMID: 36859773 PMC: 9988344. DOI: 10.1080/19420862.2023.2184197.


Modulation of Cellular Function by the Urokinase Receptor Signalling: A Mechanistic View.

Alfano D, Franco P, Stoppelli M Front Cell Dev Biol. 2022; 10:818616.

PMID: 35493073 PMC: 9045800. DOI: 10.3389/fcell.2022.818616.


Crystal structure and cellular functions of uPAR dimer.

Yu S, Sui Y, Wang J, Li Y, Li H, Cao Y Nat Commun. 2022; 13(1):1665.

PMID: 35351875 PMC: 8964761. DOI: 10.1038/s41467-022-29344-y.


Urokinase-type plasminogen activator receptor (uPAR) as a therapeutic target in cancer.

Zhai B, Tian H, Sun J, Zou J, Zhang X, Cheng J J Transl Med. 2022; 20(1):135.

PMID: 35303878 PMC: 8932206. DOI: 10.1186/s12967-022-03329-3.